COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,580 Articles (22,415 medRxiv, 8,165 bioRxiv)

Most recent first Previous |  Page 947: Articles 9461-9470  | Next

Factors Associated with COVID-19 Testing among People who Inject Drugs: Missed Opportunities for Reaching those Most at Risk
Yeager, S., Abramovitz, D., Harvey-Vera, A. Y., Vera, C. F., Algarin, A. B., Smith, L. R., Rangel, G., Artamonova, I., Patterson, T. L., Bazzi, A. R., Brugman, E. L., Strathdee, S. A.
10.1101/2022.01.04.22268749 — Posted: 2022-01-05
Validation of a novel fluorescent lateral flow assay for rapid qualitative and quantitative assessment of total anti-SARS-CoV-2 S-RBD binding antibody units (BAU) from plasma or fingerstick whole-blood of COVID-19 vaccinees
Younes, N., Al-Sadeq, D. W., Shurrab, F., Zedan, H., Abou Saleh, H., Abo Halawa, B., Al Hamaydeh, F., Elsharafi, A., Daas, H., Thomas, S., Aboalmaaly, S., Al Farsi, A., Al-Buainain, R., Ataelmannan, S., Paul, J., Saadi, A., YASSINE, H. M., Majdalawieh, A. F., Ismail, A., Abu-Raddad, L. J., Nasrallah, G.
10.1101/2022.01.04.22268754 — Posted: 2022-01-05
Autophagy and evasion of immune system by SARS-CoV-2. Structural features of the Non-structural protein 6 from Wild Type and Omicron viral strains interacting with a model lipid bilayer.
Bignon, E., Marazzi, M., Grandemange, S., Monari, A.
10.1101/2022.01.05.475107 — Posted: 2022-01-05
Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2
Santos, L. H., Kronenberger, T., Almeida, R. G., Barbosa da Silva, E., Rocha, R. E. O., Oliveira, J. C., Barreto, L. V., Skinner, D., Fajtova, P., Giardini, M. A., Woodworth, B., Bardine, C., Lourenco, A. L., Craik, C. S., Poso, A., Podust, L. M., McKerrow, J. H., Siqueira-Neto, J. L., O'Donoghue, A. J., da Silva Junior, E. N., Ferreira, R.
10.1101/2022.01.05.475095 — Posted: 2022-01-05 Discussion: Onsite
COVID-19-Associated Hospitalizations Among Children Less Than 12 Years of Age in the United States
Di Fusco, M., Vaghela, S., Moran, M. M., Lin, J., Atwell, J. E., Malhotra, D., Scassellati Sforzolini, T., Cane, A., Nguyen, J. L., McGrath, L. J.
10.1101/2022.01.04.22268742 — Posted: 2022-01-05
Radiological follow-up of adults hospitalised with pneumonia and SARS-CoV-2 infection, in Bristol UK, during the COVID19 pandemic
Ruffino, G., Williams, R. L., Barratt, S., Hyams, C.
10.1101/2022.01.04.22268738 — Posted: 2022-01-05
Evaluation of Commercial Anti-SARS-CoV-2 Neutralizing Antibody Assays in seropositive subjects
Saker, K., Pozzetto, B., ESCURET, V., Pitiot, V., Massardier-Pilonchery, A., Mokdad, B., Langlois-Jacques, C., Rabilloud, M., alfaiate, d., Guibert, N., Fassier, J.-B., BAL, A., Trouillet-Assant, S., Trabaud, M.-A.
10.1101/2022.01.04.22268652 — Posted: 2022-01-05
Fully Vaccinated and Boosted Patients Requiring Hospitalization for COVID-19: an Observational Cohort Analysis
Mielke, N., Johnson, S., Bahl, A.
10.1101/2022.01.05.22268626 — Posted: 2022-01-05 Discussion: Onsite
SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein
Walter, M., Chen, I. P., Vallejo-Gracia, A., Kim, I.-J., Bielska, O., Lam, V. L., Hayashi, J. M., Cruz, A., Shah, S., Gross, J. D., Krogan, N. J., Schilling, B., Ott, M., Verdin, E.
10.1101/2022.01.04.474979 — Posted: 2022-01-05
SARS-CoV-2 Infection of Microglia Elicits Pro-inflammatory Activation and Apoptotic Cell Death
Jeong, G. U., Lyu, J., Kim, K.-D., Chung, Y. C., Yoon, G. Y., Lee, S., Hwang, I., Shin, W.-H., Ko, J., Lee, J.-Y., Kwon, Y.-C.
10.1101/2022.01.04.475015 — Posted: 2022-01-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).